{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06001788",
            "orgStudyIdInfo": {
                "id": "KO-MEN-008"
            },
            "organization": {
                "fullName": "Kura Oncology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
            "officialTitle": "Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "safety-and-tolerability-of-ziftomenib-combinations-in-patients-with-relapsed-refractory-acute-myeloid-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT05738538",
                "statusForNctId": "AVAILABLE"
            },
            "startDateStruct": {
                "date": "2024-02-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-07",
            "studyFirstSubmitQcDate": "2023-08-14",
            "studyFirstPostDateStruct": {
                "date": "2023-08-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kura Oncology, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib."
        },
        "conditionsModule": {
            "conditions": [
                "AML",
                "AML With Mutated NPM1",
                "Hematologic Malignancy",
                "KMT2Ar",
                "NPM1 Mutation",
                "MLL Rearrangement",
                "Leukemia",
                "Acute Myeloid Leukemia",
                "Leukemia, Myeloid",
                "Leukemia, Myeloid, Acute",
                "Acute Leukemia",
                "Neoplasms by Histologic Type"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 171,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a",
                    "type": "EXPERIMENTAL",
                    "description": "Oral ziftomenib; sequential cohorts of escalating dose levels of ziftomenib to identify the safety and tolerability of the combination regimens. Participants will be enrolled in 1 of 5 dose escalation cohorts:\n\nA-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA\n\nA-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)\n\nA-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib\n\nB-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA\n\nB-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)",
                    "interventionNames": [
                        "Drug: Ziftomenib",
                        "Drug: Fludarabine",
                        "Drug: Idarubicin",
                        "Drug: Cytarabine",
                        "Drug: Gilteritinib",
                        "Biological: Granulocyte colony-stimulating factor"
                    ]
                },
                {
                    "label": "Phase 1b",
                    "type": "EXPERIMENTAL",
                    "description": "Oral ziftomenib; Following the determination of the maximum tolerated dose in Phase 1a, participants will be enrolled in 1 of 5 dose validation/expansion cohorts:\n\nA-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA\n\nA-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)\n\nA-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib\n\nB-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA\n\nB-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)",
                    "interventionNames": [
                        "Drug: Ziftomenib",
                        "Drug: Fludarabine",
                        "Drug: Idarubicin",
                        "Drug: Cytarabine",
                        "Drug: Gilteritinib",
                        "Biological: Granulocyte colony-stimulating factor"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ziftomenib",
                    "description": "Oral administration",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ],
                    "otherNames": [
                        "KO-539"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Intravenous infusion",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Idarubicin",
                    "description": "Intravenous infusion",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cytarabine",
                    "description": "Intravenous Infusion",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gilteritinib",
                    "description": "Oral administration",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ],
                    "otherNames": [
                        "Xospata"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Granulocyte colony-stimulating factor",
                    "description": "Subcutaneous injection",
                    "armGroupLabels": [
                        "Phase 1a",
                        "Phase 1b"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of dose limiting toxicities (DLTs) per dose level",
                    "description": "Assessed by the NCI-CTCAE v5.0",
                    "timeFrame": "During the first 28 days of ziftomenib in combination with SOC treatment (1 cycle)"
                },
                {
                    "measure": "Descriptive statistics of adverse events",
                    "description": "Assessed by the NCI-CTCAE v5.0",
                    "timeFrame": "First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the patient is lost to follow-up, whichever comes first"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Complete remission (CR) rate for cohorts A-1, A-2, B-1, and B-2",
                    "description": "Assessed by ELN 2022 criteria",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "Complete remission (CR) / Complete remission with partial hematologic recovery (CRh) rate for cohort A-3",
                    "description": "Assessed by ELN 2022 criteria",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "Composite complete remission (CRc) rate",
                    "description": "Assessed by ELN 2022 criteria",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "Morphologic leukemia-free state (MLFS) rate",
                    "description": "Assessed by ELN 2022 criteria",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "OS",
                    "description": "To assess overall survival",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "6-month OS",
                    "description": "To assess proportion of patients alive at 6 months",
                    "timeFrame": "Up to 6 months following discontinuation of treatment"
                },
                {
                    "measure": "Median EFS",
                    "description": "To assess median event free survival",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "6-month EFS",
                    "description": "To assess 6-month event free survival",
                    "timeFrame": "Up to 6 months following discontinuation of treatment"
                },
                {
                    "measure": "DOR",
                    "description": "To assess duration of remission",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "MRD assessment",
                    "description": "To assess minimum residual disease in bone marrow as assessed by multiparameter flow cytometry (MFC) and molecular analysis",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "HSCT",
                    "description": "To assess proportion of patients that undergo a hematopoietic stem-cell transplant",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "Transfusion independence",
                    "description": "To assess rate of transfusion independence",
                    "timeFrame": "Up to 12 months following discontinuation of treatment"
                },
                {
                    "measure": "Ziftomenib Cmax",
                    "description": "To assess the maximum plasma combination of ziftomenib and its metabolites",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Ziftomenib Tmax",
                    "description": "To assess the time to observed maximum plasma concentration of ziftomenib and its metabolites",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Ziftomenib AUC(0-last)",
                    "description": "To assess the area under the plasma concentration-time-curve from time 0 to time of last measurable concentration of ziftomenib and its metabolites",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Ziftomenib AUC(tau)",
                    "description": "To assess the area under the plasma concentration-time-curve over a dosing interval for ziftomenib and its metabolites",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Gilteritinib Cmax",
                    "description": "To assess the maximum plasma combination of gilteritinib",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Gilteritinib Tmax",
                    "description": "To assess the time to observed maximum plasma concentration of gilteritinib",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Gilteritinib AUC(0-last)",
                    "description": "To assess the area under the plasma concentration-time-curve from time 0 to time of last measurable concentration of gilteritinib",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                },
                {
                    "measure": "Gilteritinib AUC(tau)",
                    "description": "To assess the area under the plasma concentration-time-curve over a dosing interval for gilteritinib",
                    "timeFrame": "Cycle 1 (Each cycle is 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Has been diagnosed with relapsed/refractory AML.\n* Has a documented NPM1 mutation or KMT2A rearrangement.\n* Has a documented FLT3 mutation (cohort A-3 only).\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status \u2264 2.\n* Has adequate hepatic and renal function as defined per protocol.\n* Has an ejection fraction above a protocol defined limit.\n* Participant, or legally authorized representative, must be able to understand and provide written informed consent prior to the first screening procedure.\n* Has agreed to use contraception as defined per protocol.\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of acute promyelocytic leukemia or blast chronic myeloid leukemia.\n* Has clinically active central nervous system leukemia.\n* Has an active and uncontrolled infection.\n* Has a mean corrected QT interval (QTcF) \\> 480ms.\n* Has uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.\n* Has received radiation, chemotherapy, immunotherapy, or any other anticancer therapy including investigational therapy \\<14 days or within 5 drug half-lives prior to the first dose of study intervention.\n* Has had major surgery within 4 weeks prior to the first dose of study intervention.\n* Has received a hematopoietic stem cell transplant (HSCT) and has not previously had adequate recovery per protocol defined criteria.\n* Has active graft-versus-host disease (GvHD) and or on immunosuppressive drugs for the treatment of GvHD.\n* Participant is pregnant or lactating.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Operations",
                    "role": "CONTACT",
                    "phone": "858 500 8800",
                    "email": "KO-MEN-008@kuraoncology.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Development",
                    "affiliation": "Kura Oncology",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCI Health Chao Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "949-824-8170",
                            "email": "irb@uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "Smilow Cancer Hospital at Yale New Haven",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Farah Fasihuddin",
                            "role": "CONTACT",
                            "email": "farah.fasihuddin@yale.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "The University of Kansas",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66160",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "KUCC Navigation Team",
                            "role": "CONTACT",
                            "phone": "913-588-3671",
                            "email": "kucc_navigation@kumc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cathy Galasso",
                            "role": "CONTACT",
                            "email": "galassoc@karmanos.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Henry Ford Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kristyn Dailey",
                            "role": "CONTACT",
                            "email": "KDailey6@hfhs.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aaron Goldberg, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-608-3752",
                            "email": "goldbera@mskcc.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "OU Health Stephenson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cynthia J Lowery",
                            "role": "CONTACT",
                            "email": "Cynthia-Lowery@ouhsc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Prisma Health",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29615",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Johnson",
                            "role": "CONTACT",
                            "phone": "864-455-3735",
                            "email": "lisa.johnson@prismahealth.org"
                        },
                        {
                            "name": "Fiona Davidson",
                            "role": "CONTACT",
                            "phone": "864-455-3737",
                            "email": "fiona.davidson@prismahealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Allison Pike",
                            "role": "CONTACT",
                            "phone": "713-745-6756",
                            "email": "apike@mdanderson.org"
                        },
                        {
                            "name": "Ghayas C Issa, MD",
                            "role": "CONTACT",
                            "phone": "713-745-6798",
                            "email": "gcissa@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Leukemia, Myeloid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "asFound": "Neoplasms by Histologic Type",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "asFound": "Acute",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "D000015255",
                    "term": "Idarubicin"
                },
                {
                    "id": "D000078224",
                    "term": "Lenograstim"
                },
                {
                    "id": "C000609080",
                    "term": "Gilteritinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000276",
                    "term": "Adjuvants, Immunologic"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Delivered",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1945",
                    "name": "Lenograstim",
                    "asFound": "mA",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17958",
                    "name": "Idarubicin",
                    "asFound": "VEGF",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M58265",
                    "name": "Gilteritinib",
                    "asFound": "Recorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3628",
                    "name": "Adjuvants, Immunologic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}